Avoid common mistakes on your manuscript.
To the Editor
Homozygous loss-of-function mutations of the IKBKB gene, encoding inhibitor kappa B kinase 2 (IKKβ or IKK2) protein, are a known cause for autosomal recessive severe combined immunodeficiency (SCID) albeit with low levels of immunoglobulins but relatively normal T and B cell counts [1]. Heterozygous gain-of-function (GOF) mutations in the same gene have been reported to cause an autosomal dominant hypomorphic combined immunodeficiency disorder with moderate lymphocytopenia and hypogammaglobulinemia. Clinical symptoms have so far been characterized by recurrent sinopulmonary infections, immune dysregulation and epithelial defects with a cutaneous phenotype [2, 3].
We present the case of a fatal disseminated hepatitis E infection in a 52 year old female caucasian patient of German residence with IKBKB mutation. The patient was diagnosed with chronic hepatitis E in 2017 without previous hepatic diseases. Apart from one herpes zoster infection 10 years earlier and a stable erythematotelangiectatic rosacea stage I-II with central facial distribution since early adulthood, the patient did not show an increased susceptibility to infections, autoimmunity, lymphoproliferation or other relevant medical conditions. As chronic hepatitis E is known to occur in immunosuppressed individuals such as transplant patients, immunological work-up was initiated.
Immunological work-up revealed normal IgG, IgA and IgM levels but a combined IgG2/IgG4-subclass deficiency and non-detectable antibodies against pneumococcal vaccine (specific pneumococcal-IgG remained below detection levels after sequential conjugated and polysaccharide vaccination). The patient was a known hepatitis B non-responder. HEV-IgG was detectable as well as specific IgG antibodies against tetanus toxoid and diphteria toxoid. In addition, lymphocyte phenotyping showed significantly reduced CD4 + and CD8 + T cells (150/µl and 120/µl respectively) with diminished proportion of CD45RA + CD4 + naïve T cells of 1–2%. CD19 + B cells had normal counts but expressed greatly decreased percentage of class-switched memory B cells (0,3% of CD19 + B cells) (see Table 1). Whole exome sequencing identified a previously reported heterozygous mutation in IKBKB (c.607G > A; p.V203I) (cDNA.793G > A, g.37639G > A). No other probable germline or somatic mutation was identified. Segregation analysis of the patient’s non-consanguineous parents was not possible. Type I interferon (IFN) autoantibodies (IFN alpha and IFN omega) were undetectable.
Off-label treatment with ribavirin was without clinical benefit and viral copy load of hepatitis E virus (HEV) persisted at a high level (> 5.000.000 IU/ml). Our patient was started on immunoglobulin substitution therapy. However, persistently elevated viral load of HEV required repeated treatment with ribavirin alone or in combination with interferon. Treatment was stopped due to severe hematopoetic adverse events requiring weekly transfusions and treatment with Thrombopoetin receptor agonist Eltrombopag (see supplemental table S1).
Viral load continued to remain high and the clinical condition deteriorated. In 09/2019 the patient was admitted to hospital due to acute on chronic liver failure. New neuro-psychological symptoms were first regarded as hepatic encephalopathy. In the absence of hyperammonemia further diagnostic work-up was conducted and revealed a positive PCR for HEV in cerebrospinal fluid (CSF). No other pathogens were detected by Multiplex PCR in CSF. Patient was admitted to ICU with clinical symptoms of septic shock and tonic-clonic seizure. Our patient deceased shortly thereafter without identification of other pathogens.
Post-mortem autopsy revealed liver cirrhosis without any other relevant organ pathology including no signs of neuro-inflammation or –degeneration. To assess the role of HEV we further analyzed different tissue samples from duodenum, liver and medulla oblongata and tested for the presence of HEV. HEV RNA and HEV specific RT-qPCR was conducted [4] and was positive in all tissue types. Interestingly, we observed differences in the consensus sequence in different tissues suggesting independent viral replication and a rare case of disseminated hepatitis E infection and compartmentalization.
We describe a case of a chronic hepatitis E with disseminated and fatal outcome in an adult female patient with no previous signs for an immunocompromised state and consequently diagnosed a heterozygous gain-of-function (GOF) IKBKB variant. The variant has undergone functional testing before and NFKB activation was shown by others [2].
Hepatitis E virus (HEV) is a hepatotropic RNA virus that is a rare cause of acute liver failure and usually does not lead to chronic infections in healthy individuals. Of four genotypes, genotype 3 is almost universally the cause in Europe, and the genotype does not influence the propensity to chronic infection. Impaired HEV epitope-specific CD4+ and CD8+ T cell responses are associated with the development of chronic hepatitis E [5], a defect that may explain the chronic infection in our patient. Chronic HEV is well-described in patients with solid organ transplantation, human immunodeficiency virus patients with low CD4 counts, in patients with hematological malignancy and in those receiving systemic chemotherapy.
Considering the high prevalence of hepatitis E with an IgG-seropositivity rate of approximately 10–20% in the general population, the underlying pathomechanisms of chronic hepatitis E infection remain poorly defined. So far, no other cases of chronic hepatitis E have been reported in IKBKB GOF patients. It remains to be determined, whether the chronic and fatal disease course is related to the mutation in IKBKB. However, other known risk factors for a chronification of hepatitis E were not identified.
A limitation to our reported case is that we did not assess T cell specific immunity to HEV. In addition, we never had the opportunity to conduct an in-depth immunological phenotyping before the onset of the chronic hepatitis E infection. In particular, the repeated treatment with ribavirin is very likely to have affected the hematopoietic compartment. Similarly, we could not identify additional autoinflammatory aspects in our patient, as was described previously [3].
Our findings highlight once again that all patients with unusual infections should be screened for an underlying immunodeficiency. Our case broadens the clinical picture of GOF mutations in IKBKB, showing that some individuals can present with a combined immunodeficiency later in adulthood with profound T-cell deficiency and impaired vaccination response, in this case leading to a disseminated and fatal hepatitis E infection.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
References
Pannicke U, Baumann B, Fuchs S, Henneke P, Rensing-Ehl A, Rizzi M, et al. Deficiency of innate and acquired immunity caused by an IKBKB mutation. N Engl J Med. 2013;369(26):2504–14.
Cardinez C, Miraghazadeh B, Tanita K, da Silva E, Hoshino A, Okada S, et al. Gain-of-function IKBKB mutation causes human combined immune deficiency. J Exp Med. 2018;215(11):2715–24.
Sacco K, Kuehn HS, Kawai T, Alsaati N, Smith L, Davila B, et al. A heterozygous gain-of-function variant in IKBKB Associated with autoimmunity and autoinflammation. J Clin Immunol. 2023;43(2):512–20.
Melchert J, Radbruch H, Hanitsch LG, Baylis SA, Beheim-Schwarzbach J, Bleicker T, et al. Whole genome sequencing reveals insights into hepatitis E virus genome diversity, and virus compartmentalization in chronic hepatitis E. J Clin Virol. 2023;168:105583.
Suneetha PV, Pischke S, Schlaphoff V, Grabowski J, Fytili P, Gronert A, et al. Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. Hepatology. 2012;55(3):695–708.
Acknowledgements
We acknowledge Katrin Lutz, Julia Benckert and Daniel Zickler for their involvement in clinical management.
Funding
The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.
Open Access funding enabled and organized by Projekt DEAL.
Author information
Authors and Affiliations
Contributions
Conceptualization: Leif G. Hanitsch; Sourcing of patient samples: Leif G. Hanitsch, Marion Muche, Helena Radbruch; Methodology: Victor M Corman; Formal analysis and investigation: Victor M Corman, Jörg Hofmann, Helena Radbruch; Analysis of results and composition of tables: Leif G Hanitsch; Interpretation of data: Leif G. Hanitsch; Writing - review and editing: all authors. All authors gave final approval of the version to be published.
Corresponding author
Ethics declarations
Ethics Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee of Charité, Universitätsmedizin Berlin (EA2/092/20 from June 4th, 2020) and with the 1964 Helsinki Declaration and its later amendments.
Consent to Participate
Informed consent was obtained from the participating patient and the family.
Consent to Publish
The authors affirm that human research participants provided informed consent for publication of acquired data.
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic Supplementary Material
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Hanitsch, L.G., Muche, M., Radbruch, H. et al. Fatal Disseminated Hepatitis E in an Adult Patient with IKBKB GOF Mutation. J Clin Immunol 44, 120 (2024). https://doi.org/10.1007/s10875-024-01721-w
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s10875-024-01721-w